Core Points - Picard Medical, Inc. successfully closed its initial public offering (IPO) of 4,250,000 shares at a price of $4.00 per share, generating gross proceeds of $17 million before deductions [1] - The company has granted underwriters an option to purchase an additional 637,500 shares to cover over-allotments within 30 days of the offering [1] - The shares began trading on the NYSE American under the ticker symbol "PMI" on August 29, 2025 [1] Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is recognized as the leader in total artificial heart technology for patients with end-stage heart failure [5] - The SynCardia Total Artificial Heart (STAH) is the only commercially available artificial heart approved by both the FDA and Health Canada, with over 2,100 implants performed across 27 countries [5] - The STAH is noted for being the most widely used and extensively studied artificial heart globally [5]

Core Points - iSpecimen Inc. closed a private placement for approximately $1.75 million in gross proceeds, intended for marketing and working capital [1][2][3] - The company issued 1,559,828 shares of common stock at a price of $1.122 per share [2] - WestPark Capital, Inc. acted as the exclusive placement agent for the offering [3] Financial Details - The net proceeds will be allocated as follows: $500,000 for marketing and advertising services, with the remainder for working capital and general corporate purposes [1] - The offering closed on August 4, 2025 [2] Company Overview - iSpecimen operates an online marketplace connecting scientists with healthcare specimen providers for medical research [6] - The company utilizes proprietary cloud-based technology to facilitate the search for biospecimens across a network of healthcare organizations [6]

Company Overview - iSpecimen Inc. operates an online global marketplace connecting scientists with healthcare specimen providers for medical research [6] - The company utilizes proprietary cloud-based technology to facilitate the search for biospecimens and patients across a network of healthcare organizations [6] Recent Offering - On July 25, 2025, iSpecimen announced the closing of an underwritten public offering of 5,714,283 shares at a price of $0.70 per share, generating approximately $4 million in gross proceeds [2][3] - The offering was conducted on a firm commitment basis, with WestPark Capital, Inc. serving as the Sole Book-Runner [3] Use of Proceeds - The net proceeds from the offering will be allocated as follows: $1.5 million for marketing and advertising services from IR Agency LLC, $1 million for an initial milestone payment to Sales Stack Solutions Corp., and the remainder for working capital and general corporate purposes [3] Regulatory Compliance - The securities offered are pursuant to a registration statement on Form S-1, which was declared effective by the SEC on July 23, 2025 [4]

Core Viewpoint - iSpecimen Inc. announced a public offering of 5,714,283 shares at a price of $0.70 per share, aiming to raise approximately $4 million in gross proceeds before expenses [2][3]. Group 1: Offering Details - The public offering is expected to close on July 25, 2025, pending customary closing conditions [2]. - The net proceeds from the offering will be allocated as follows: $1.5 million for marketing and advertising services, $1 million for an initial milestone payment to Sales Stack Solutions Corp., and the remainder for working capital and general corporate purposes [3]. Group 2: Company Overview - iSpecimen operates an online marketplace connecting scientists with healthcare providers for biospecimens needed in medical research, utilizing proprietary cloud-based technology [6].

Core Viewpoint - iSpecimen Inc. has successfully closed a public offering of 5,714,283 shares at a price of $0.70 per share, raising approximately $4 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The public offering was conducted on a firm commitment basis, with WestPark Capital, Inc. serving as the Sole Book-Runner [2]. - The offering price was set at $0.70 per share, resulting in gross proceeds of around $4 million [1][2]. Group 2: Use of Proceeds - The company plans to allocate $1,500,000 for marketing and advertising services from IR Agency LLC [2]. - An initial milestone payment of $1,000,000 will be made under a definitive agreement with Sales Stack Solutions Corp. [2]. - The remaining funds will be used for working capital and general corporate purposes [2]. Group 3: Company Overview - iSpecimen operates an online marketplace connecting scientists with healthcare providers for biospecimens needed in medical research [5]. - The company utilizes proprietary, cloud-based technology to facilitate searches for specimens and patients across a network of healthcare organizations [5].

Core Viewpoint - iSpecimen Inc. has announced a public offering of 5,714,283 shares at a price of $0.70 per share, aiming to raise approximately $4 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The public offering is priced at $0.70 per share, with expected gross proceeds of around $4 million [1]. - The offering is set to close on July 25, 2025, pending customary closing conditions [1]. - WestPark Capital, Inc. is acting as the Sole Book-Runner for the offering [2]. Group 2: Use of Proceeds - The company plans to allocate $1,500,000 for marketing and advertising services from IR Agency LLC [2]. - An initial milestone payment of $1,000,000 will be made to Sales Stack Solutions Corp. [2]. - Remaining funds will be used for working capital and general corporate purposes [2]. Group 3: Company Overview - iSpecimen operates an online marketplace connecting scientists with healthcare specimen providers for medical research [5]. - The company utilizes proprietary cloud-based technology to facilitate searches for biospecimens across a network of healthcare organizations [5].

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has successfully closed a public offering of 19,166,667 shares at a price of $0.30 per share, raising approximately $5.75 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The public offering consisted of common stock and pre-funded warrants, with the total gross proceeds amounting to about $5.75 million [1]. - The offering was conducted on a firm commitment basis, with WestPark Capital, Inc. serving as the Sole Book-Runner [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to fund a Phase II clinical trial for the company's lead product candidate, as well as for marketing, advertising services, working capital, and general corporate purposes [2]. Group 3: Company Background - Shuttle Pharmaceuticals, founded in 2012 by faculty members of Georgetown University Medical Center, focuses on improving outcomes for cancer patients undergoing radiation therapy [5]. - The company's mission is to enhance the effectiveness of radiation therapy while minimizing side effects, aiming to increase cancer cure rates and improve patient quality of life [5].

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has announced a public offering of 19,166,667 shares at a price of $0.30 per share, aiming to raise approximately $5.75 million to fund its Phase II clinical trial and other corporate purposes [1][2]. Group 1: Offering Details - The public offering is priced at $0.30 per share, with expected gross proceeds of about $5.75 million before expenses [1]. - The offering is set to close on March 13, 2025, pending customary closing conditions [1]. - WestPark Capital, Inc. is acting as the Sole Book-Runner for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to fund the Phase II clinical trial for the lead product candidate, marketing and advertising services, and general corporate purposes [2]. Group 3: Company Overview - Shuttle Pharmaceuticals, founded in 2012, focuses on improving outcomes for cancer patients undergoing radiation therapy by developing therapies that enhance the effectiveness of radiation while minimizing side effects [5]. - The company aims to increase cancer cure rates and improve patient quality of life through the development of radiation sensitizers [5].